Global Benchmark for Efficient Drug Pricing Model (GLOBE)

Analysis updated November 9, 2026

Strategic questions for your team

Which of our currently administered Part B drugs fall within the oncology, rheumatology, immunology, ophthalmology, and endocrinology therapeutic classes with annual Original Medicare spending exceeding $100 million — and what is our current revenue exposure from those specific agents between January 1, 2027 and March 31, 2032?
How will the GLOBE Model's beneficiary coinsurance reduction (effective April 1, 2027 through March 31, 2032) affect our net collections per drug administration claim, given that Medicare payment is calculated as the allowed amount minus the GLOBE Model beneficiary coinsurance amount, and have we modeled the downstream impact on our 340B spread, buy-and-bill margin, and average sales price (ASP)-based reimbursement for each affected drug?
Do we have the billing system and revenue cycle infrastructure in place to correctly adjudicate GLOBE Model-adjusted coinsurance amounts beginning April 1, 2027, including the ability to identify GLOBE-eligible beneficiaries by geographic area, apply the adjusted allowed amount calculation, and reconcile against manufacturer rebates flowing to the Medicare SMI Trust Fund rather than to our organization?
Since manufacturer rebates under GLOBE bypass providers entirely and flow directly to the Medicare Supplementary Medical Insurance Trust Fund, what is our strategic plan to offset margin compression on high-cost single-source biologics and sole-source biological products in our formulary — particularly for infused oncology and autoimmune therapies where buy-and-bill economics are most sensitive to ASP fluctuations?
What is our patient access contingency plan if international benchmark pricing causes certain GLOBE Model drugs to become commercially less available or if manufacturers respond to rebate pressure with supply restrictions between 2027 and 2032 — and have our CMO and pharmacy leadership mapped therapeutic alternatives for each drug class at risk?
How does our payer mix across the affected therapeutic classes break down between Original Medicare Part B (directly subject to GLOBE) and Medicare Advantage (not directly subject to GLOBE coinsurance reductions), and does a shift in relative attractiveness between Original Medicare and MA for high-cost drug administration change our contracting or site-of-care strategy through 2032?
Have we assessed which of our geographic service areas are included in the GLOBE Model's geographic selection criteria for beneficiary eligibility, and do we have a clear operational process to identify in real time which patients qualify for reduced coinsurance so that front-end financial counseling and prior authorization workflows are updated before the January 1, 2027 launch?
What is our reconciliation and accounts receivable reserve strategy for the period extending through 2034, when GLOBE Model rebate invoicing and reconciliation continue after the March 31, 2032 model end date — and have our CFO and external auditors stress-tested the multi-year tail liability this creates for cost reporting, bad debt calculations, and financial statement disclosures?
For our physician group and employed specialist practices that administer GLOBE Model drugs in office-based settings, have we quantified the comparative financial impact relative to hospital outpatient department (HOPD) administration, and does GLOBE Model reimbursement pressure create a site-of-care migration risk that favors or disfavors our current care delivery footprint?
Given that GLOBE is a mandatory model running from January 1, 2027 through March 31, 2032 with no opt-out provision for providers treating eligible beneficiaries, what is our board-level governance and scenario planning process to monitor whether CMS — under the current Trump administration leadership at CMMI — modifies, pauses, or expands the model's drug selection criteria or reference country list before the 2027 launch, and who is accountable internally for tracking regulatory developments through the Federal Register?
Now that CMS has finalized the GLOBE Model with savings projections that trail earlier projections, have we obtained and reviewed the final rule to confirm whether drug selection criteria, reference country list, rebate methodology, or geographic scope were materially narrowed from the proposed rule — as reported by ASCO — in ways that reduce or shift our exposure relative to earlier modeling assumptions?
The Endpoints News reporting on an internal CMS email indicates that drugmakers who agree to provide additional Medicaid rebates may be exempted from GLOBE — have we identified which manufacturers of drugs we currently administer are likely to pursue this exemption pathway, and have we modeled the impact on our drug mix, ASP-based reimbursement, and buy-and-bill economics if key high-spend agents are removed from GLOBE coverage mid-model or at launch?
Given the finalized most-favored-nation pricing structure under GLOBE and the manufacturer Medicaid rebate exemption pathway, what is our government affairs and supply chain strategy to engage with manufacturers of our highest-revenue Part B drugs regarding their GLOBE participation status, potential formulary substitution dynamics, and any contractual implications for our group purchasing organization or 340B covered entity agreements?
Now that PhRMA has filed suit against the Trump administration to block the GLOBE model, what is our legal and operational contingency strategy if a court issues a preliminary injunction or stay that delays or invalidates the model after January 1, 2027 — including how we would unwind any billing system changes, financial counseling workflows, or contracting adjustments already implemented in reliance on GLOBE's effective date?
Given that PhRMA's litigation against GLOBE creates meaningful implementation uncertainty through 2027 and potentially beyond, how should we stage our operational readiness investments — such as revenue cycle reprogramming, staff training, and formulary restructuring — to preserve flexibility if the model is enjoined, modified by court order, or ultimately vacated, and what go/no-go decision gates have we established ahead of the January 1, 2027 launch date?

Traps and concerns

International Benchmark Data Lag and Accuracy Risk
The GLOBE Model benchmark is derived from either manufacturer-reported international net pricing data or commercially available data sources covering 19 reference countries (Australia, Austria, Belgium, Canada, Czech Republic, Denmark, France, Germany, Ireland, Israel, Italy, Japan, Netherlands, Norway, South Korea, Spain, Sweden, Switzerland, and UK). Manufacturer participation in voluntary net pricing data submission is optional, meaning CMS may default to commercially available sources that reflect list prices rather than true net prices (after rebates and discounts applied in those countries). If international net prices are systematically understated or lagged, the benchmark will be artificially low, triggering rebate obligations that exceed the actual pricing differential. For manufacturers, this creates exposure to rebate invoices that cannot be reconciled against accurate international comparators. For providers and suppliers, reimbursement adjustments tied to an inaccurate benchmark could compress Part B margins on high-spend oncology, rheumatology, immunology, ophthalmology, and endocrinology drugs — the exact therapeutic classes where buy-and-bill economics are most sensitive.
Buy-and-Bill Cash Flow Disruption (2027–2032)
Under GLOBE, the Original Medicare Part B payment to providers is calculated as the allowed amount minus the GLOBE Model beneficiary coinsurance amount, with the reduced coinsurance period running April 1, 2027 through March 31, 2032. Providers operating under buy-and-bill — acquiring high-cost Part B drugs (oncology, rheumatology, immunology drugs with annual Original Medicare spending exceeding $100 million per drug) at ASP+6% reimbursement — will see their net payment reduced as the coinsurance reduction is carved out. If ASP is not simultaneously adjusted downward to reflect the international benchmark, providers absorb the spread between drug acquisition cost and a reduced Medicare payment. Hospitals and physician practices with high volumes of GLOBE Model drugs must model this cash flow gap beginning January 1, 2027, when the model launches, and sustain operations through the five-year run with reconciliation extending into 2034.
Rebate Invoicing and Reconciliation Tail Risk (Into 2034)
The GLOBE Model runs through March 31, 2032, but rebate invoicing and reconciliation continue into 2034 — a two-year administrative tail. Manufacturers face the risk of retroactive rebate adjustments as CMS reconciles international benchmark data against actual Medicare Part B claims. For health systems and ACOs that have structured budgets and drug spend projections around model parameters, late reconciliation adjustments can create unexpected liability or revenue restatements affecting fiscal years 2032–2034. Manufacturers must maintain robust data retention and dispute resolution capabilities for mandatory rebate obligations across a roughly seven-year compliance window (2027–2034). Finance teams should budget for contingent liabilities well beyond the model's operational end date.
Mandatory Participation Triggers Without Drug-Level Opt-Out — Now Under Active Legal Challenge
Participation is mandatory for pharmaceutical manufacturers of any Medicare Part B drug meeting GLOBE Model drug eligibility criteria: single-source drugs or sole-source biological products in oncology, rheumatology, immunology, ophthalmology, or endocrinology with annual Original Medicare spending exceeding $100 million, subject to certain exceptions. Manufacturers cannot selectively exclude individual high-exposure drugs from their portfolio. The only discretionary element is the voluntary submission of international net pricing data. PhRMA filed suit against the Trump administration following finalization of the GLOBE rule, directly challenging mandatory participation. This litigation creates material implementation uncertainty: if a court grants a preliminary injunction, mandatory rebate obligations could be stayed before the January 1, 2027 launch, disrupting compliance timelines for both manufacturers and providers. Operational and financial planning must simultaneously track litigation milestones and prepare for full mandatory compliance, as a failed legal challenge would leave manufacturers with no exit mechanism and compressed time to operationalize.
Medicaid Rebate Exemption Trade-Off Creates Cross-Program Compliance Complexity
Internal CMS correspondence confirmed that CMS has structured an exemption pathway under which drugmakers may avoid GLOBE Model rebate obligations if they agree to provide additional rebates in Medicaid. This Medicaid-for-GLOBE trade-off — also confirmed to apply to the GUARD model — creates a novel cross-program compliance decision point for manufacturers. Manufacturers evaluating this exemption must model the net financial impact of enhanced Medicaid rebates versus GLOBE mandatory rebates across their entire product portfolio, including products not covered by GLOBE. Accepting the Medicaid exemption pathway could also set a precedent for future CMS models to leverage Medicaid rebate enhancements as an opt-out lever, potentially expanding rebate obligations across state programs. State Medicaid agencies and managed Medicaid plans should monitor whether enhanced rebates negotiated under this exemption pathway flow through to state drug spend or are absorbed at the federal level.
Beneficiary Geographic Selection and Equity Compliance Risk
GLOBE Model beneficiary inclusion is determined based on geographical area — not individual beneficiary election. This creates a two-tier beneficiary experience where Medicare Part B enrollees in selected geographies receive reduced coinsurance tied to the international benchmark (effective April 1, 2027 through March 31, 2032) while those outside the model geography pay standard coinsurance. Providers operating across geographic boundaries — large health systems, multi-site oncology practices, or integrated delivery networks — must operationally identify which patients trigger GLOBE Model coinsurance reductions versus standard billing at point of service. Misapplication of coinsurance amounts constitutes a billing compliance risk. Additionally, geographic selection that correlates with demographic or socioeconomic factors could attract scrutiny under CMS equity requirements and CMMI's stated commitment to health equity, potentially generating regulatory or political pressure on model design mid-implementation.
EHR and Billing System Reconfiguration for Dual Coinsurance Logic
Providers must configure EHR and practice management systems to apply two distinct coinsurance calculation pathways for affected Part B drugs: the standard Medicare Part B coinsurance rate and the reduced GLOBE Model coinsurance amount tied to the international benchmark. Given that GLOBE Model drugs span multiple therapeutic classes (oncology, rheumatology, immunology, ophthalmology, endocrinology) with an annual Medicare spending threshold above $100 million and a drug list that may evolve as CMS selects and updates qualifying drugs, billing system logic must be dynamic rather than static. Implementation timelines are compressed — the model launches January 1, 2027, with coinsurance reductions effective April 1, 2027, leaving fewer than 12 months from a typical procurement-to-deployment cycle for IT system updates. Health systems and large physician groups that have not begun vendor engagement and system design by mid-2026 face material compliance risk at go-live.
Drug List Volatility and Formulary Access Disruption
GLOBE Model drugs are selected from Part B rebatable single-source and sole-source biological products in targeted therapeutic classes where annual Original Medicare spending exceeds $100 million. Because drug eligibility is determined by CMS and can change across the model period (January 1, 2027 through March 31, 2032), manufacturers face the risk that newly approved products crossing the $100 million threshold mid-model are retroactively captured by mandatory rebate obligations. For oncology and immunology drug manufacturers launching products in 2026–2028, modeling entry into GLOBE Model eligibility must be integrated into launch economics and contracting strategy. Providers and formulary managers should also anticipate the possibility that mandatory rebate pressure creates incentives for manufacturers to limit Medicare Part B access or shift distribution strategies for high-cost qualifying drugs, potentially disrupting established patient access pathways.
Finalized Savings Projections Trail Earlier Estimates — Reduced Political and Budget Justification
At finalization, CMS's projected savings from the GLOBE Model are significantly lower than previously projected, according to reporting on the final rule. This gap between anticipated and finalized savings estimates creates political and budgetary risk for the model: Congressional budget scorekeepers and deficit-reduction advocates who supported GLOBE on the basis of earlier projections may view the model as underdelivering on its core rationale. A weaker savings case reduces the model's political insulation against future challenge, legislative defunding, or administrative rescission. For manufacturers already locked into mandatory rebate obligations, a low-savings finding also increases the likelihood that CMS will pursue model modifications or extensions that increase rebate stringency to close the gap, potentially creating mid-model parameter shifts that disrupt financial planning assumptions established at launch.
Scope Narrowing in Final Rule Creates Stranded Planning Costs and Renegotiation Exposure
Reporting by ASCO and others confirms that the scope and financial impact of the GLOBE Model were narrowed between the proposed and final rule. Manufacturers, health systems, and specialty practices that sized compliance infrastructure, legal review, and contract renegotiation efforts based on the proposed rule's broader scope have incurred planning costs against a smaller actual exposure. More critically, narrowing of scope mid-rulemaking signals that CMS may further adjust model parameters — through subregulatory guidance, interim final rules, or model redesign — in response to litigation pressure from PhRMA or political developments, creating ongoing uncertainty about which drugs, geographies, and rebate thresholds will govern actual compliance obligations between now and the January 1, 2027 launch.